2nd Quarter - Report

OREGON HEALTH & SCIENCE UNIVERSITY for OREGON HEALTH & SCIENCE UNIVERSITY

Firm
Client
Income
—
Expenses
$60,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

9 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Adequacy of health care workforce associated with expansion of health care coverage.

LobbyistCovered position, as disclosed
LYNNE DAVIS BOYLE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Veterans VET

Access to care for veterans and physician workforce issues.

LobbyistCovered position, as disclosed
LYNNE DAVIS BOYLE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

Impact of Budget Control Act of 2011's Sequestration on medical research; use of animals in biomedical research; moving medical research from bench to bedside more quickly including greater sharing of research data, reducing administrative burden on medical researchers, streamlining of clinical trials, increased flexibility in the FDAs approval processes for drugs and devices tied with additional review in post-market: 21st Century Cures Act (HR 6); FDA regulation of mitochondrial replacement therapy Sections 736 in Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017 (HR 5054/ S.2956); importance of research using fetal tissue; importance of Small Business Innovation Research and Small Technology Transfer Research programs.

LobbyistCovered position, as disclosed
LYNNE DAVIS BOYLE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5054 (114th), H.R. 6 (114th), S. 2956 (114th)

Animals ANI

Use of animals in biomedical research.

LobbyistCovered position, as disclosed
LYNNE DAVIS BOYLE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

Maintaining the current charitable tax deduction.

LobbyistCovered position, as disclosed
LYNNE DAVIS BOYLE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Pharmacy PHA

340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance.

LobbyistCovered position, as disclosed
LYNNE DAVIS BOYLE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Protecting innovators from frivolous patent lawsuits: "Innovation Act" (HR 9).

LobbyistCovered position, as disclosed
LYNNE DAVIS BOYLE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 9 (114th)

Medicare/Medicaid MMM

Preventing cuts to Medicare Graduate Medical Education payments: The Medicare IME Pool Act of 2015 (H.R. 3292); preventing cuts to Disproportionate Share Hospital Payments: The Strengthening DSH and Medicare Through Subsidy Recapture and Payment Reform Act of 2015 (H.R. 3288); Preventing reductions to Hospital Inpatient and Outpatient PPS Payments: The Medicare Crosswalk Hospital Code Development Act of 2015 (H.R. 3291), Section 603 Bipartisan Budget Act of 2015 (1314) Helping Hospitals Improve Patient Care Act of 2016 (HR 5273); Provider reimbursements for end of life care counseling; Additional Medicare support for Medicare Graduate Medical Education; Allowing nurse practitioners, certified nurse-midwives, and clinical nurse specialists to certify home health services for Medicare patients: "Home Health Care Planning Improvement Act (S 578); Medicare payment for short hospital stays; Preventing reductions to the Medicaid program including the provider tax; Improvements to the Medicaid program for medically complex children: "Advancing Care for Exceptional Children Act of 2015" (HR 546/S 298).

LobbyistCovered position, as disclosed
LYNNE DAVIS BOYLE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5273 (114th), H.R. 546 (114th), H.R. 3288 (114th), H.R. 3291 (114th), H.R. 3292 (114th)

Budget/Appropriations BUD

FY 2017 funding for NIH, Title VII and VIII of the Public Health Services Act, Centers for Disease Control, Agency for HealthCare Research and Quality, Healthcare Resources and Services Administration, Office of Refugee Resettlement; Maternal Child Health Bureau; FY2017 funding for National Science Foundation; FY 2017 funding for USGS Columbia River program; FY 2017 funding for Department of Defense Health Research and for environmental exposures biomarkers research and lung injury research; FDA regulation of mitochondrial replacement therapy Sections 736 in Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017 (HR 5054/ S.2956); FY2017 funding for Zika: Zika Response Appropriations Act, 2016 (HR5243), Division B in Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2017 (HR 2577).

LobbyistCovered position, as disclosed
LYNNE DAVIS BOYLE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5054 (114th), H.R. 5243 (114th), S. 2956 (114th), H.R. 2577 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.